Opinion on Pharmaceuticals in North America

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
Expert View
Expert View

AD/PD 2011: Alzheimer's companies showcase new data for marketed brands

Datamonitor recently attended the 10th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2011) in Barcelona, Spain, held over March 9-13, 2011. Below are the highlights of the conference's coverage of currently marketed treatments for both diseases.

Published By Datamonitor
24 Mar 2011
Expert View
Expert View

AD/PD 2011: far too early to lay beta-amyloid hypothesis to rest

Datamonitor recently attended the 10th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2011) in Barcelona, Spain, held over March 9-13, 2011. Below are the highlights of the conference's coverage of pipeline Alzheimer's drugs.

Published By Datamonitor
24 Mar 2011
CommentWire
CommentWire

ADHD: attending to safety deficits

An FDA safety committee is to meet in February to discuss how ADHD drug safety risks can be better assessed. The meeting will give further insight into how the FDA plans to deal with the problem, and the regulator's proposals may include recommending drug makers conduct extra long-term treatment trials. This would be a wise move in the interests of drug companies, patients and physicians alike.

Published By Datamonitor
05 Jan 2006
CommentWire
CommentWire

ADHD: FDA debates black box warnings

In a controversial move, an FDA panel has recommended against ADHD drugs bearing "black box" warnings about psychiatric and cardiovascular risks in children. While the regulator's final decision will be eagerly awaited by both patients and drug makers alike it looks like Eli Lilly's Strattera will remain standing strong whatever the ruling.

Published By Datamonitor
24 Mar 2006
CommentWire
CommentWire

Advanced Life Sciences: aiming for second place with cethromycin

Considering the strong launch of the only ketolide currently available, Sanofi-Aventis' Ketek, Advanced Life Sciences' antibiotic cethromycin is expected to perform well in its first few years on the market, once approved. Indeed, with off-label use, cethromycin revenues could reach $145 million by 2010, beating Wall Street consensus of $123 million. However, Ketek will remain a formidable rival.

Published By Datamonitor
14 Jun 2006
ResearchWire
ResearchWire

Advanced Life Sciences: aiming for second place with cethromycin

Published By Datamonitor
30 Jun 2006
Expert View
Expert View

AHA 2010: a selection of the key highlights

The 2010 American Heart Association Scientific Sessions in Chicago (November 13-17) were relatively quiet, with Bayer's Xarelto and Merck's anacetrapib proving to be the main attractions. However, Datamonitor expects that data presented on cardiorenal sydromes, critical limb ischemia, and cachexia in heart failure will also have an impact on the future of cardiovascular drug development.

Published By Datamonitor
29 Nov 2010
Expert View
Expert View

AIDS 2010: promising developments for novel HIV agents and strategies

Given the abundance of therapeutic options for HIV treatment, companies are increasingly looking to simplify therapy through the development of cross-class combinations and nucleoside-sparing strategies to minimize toxicity. Many of the pipeline drugs highlighted at this year's International AIDS Conference brought this new direction of development into focus.

Published By Datamonitor
27 Jul 2010
CommentWire
CommentWire

Alexion: good news for new asthma approach

Alexion has demonstrated the efficacy of an inhaled monoclonal anti-C5 antibody to block airway hyper-responsiveness in preclinical models. This is clearly good news for what looks like an interesting and convenient new approach to treating those asthma patients who remain insufficiently controlled on existing drugs, although the drug candidate has a long way to go yet.

Published By Datamonitor
17 May 2006
CommentWire
CommentWire

Alkermes and Cephalon: Vivitrol's sales likely to be unaffected by FDA's warning

The FDA has warned of the risk of injection site reactions to Vivitrol, a once-monthly injection drug for the treatment of alcohol dependence. However, due to the considerable adverse health consequences related to alcohol dependence, along with the limited number of prescription drugs available, Datamonitor does not expect Vivitrol to experience a substantial downturn in sales.

Published By Datamonitor
13 Aug 2008

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.